N
CARM

Nuveen’s Carisma Therapeutics CARM Stock Holding History

Nuveen’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-102,702
Closed -$233K – 3345
2024
Q1 		$233K Hold
102,702
– – ﹤0.01% 3151
2023
Q4 		$301K Buy
102,702
+2,914
+3% +$8.66K ﹤0.01% 3146
2023
Q3 		$422K Hold
99,788
– – ﹤0.01% 2898
2023
Q2 		$875K Buy
+99,788
New +$543K ﹤0.01% 2715
2022
Q2 		– Sell
-26,322
Closed -$3.11M – 3275
2022
Q1 		$3.11M Hold
26,322
– – ﹤0.01% 2300
2021
Q4 		$3.11M Sell
26,322
-12,500
-32% -$252K ﹤0.01% 2359
2021
Q3 		$4.58M Sell
38,822
-518
-1% -$24.9K ﹤0.01% 2264
2021
Q2 		$3.63M Buy
+39,340
New +$2.51M ﹤0.01% 2407

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $93.1B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return